Table 3.
Drug-eluting stents (DES) with nonbiodegradable polymer surfaces available on the market or during clinical trials [58].
| Trade Name. | Stent Platform | Polymer System | Drug | Drug Release (Days) | Manufacturer | Approval |
|---|---|---|---|---|---|---|
| Cypher® | SS | PEVA, PBMA, PCh | Sirolimus | 40% (5) 85% (30) 100% (90) |
Cordis Corporation (Hialeah, FL) | FDA, CE |
| Taxus® | SS | Poly(styrene-b-isobutylene-b-styrene) | Paclitaxel | <10% (28) | Boston Scientific (Marlborough, MA) | FDA, CE |
| Promus PREMIERTM | Pt-Cr | PBMA, poly(vinylidene-co-hexafluoropropylene) | Everolimus | 71% (28) 100% (120) |
Boston Scientific (Marlborough, MA) | FDA, CE |
| Xience V® | Co-Cr | PBMA, poly(vinylidene-co-hexafluoropropylene) | Everolimus | 80% (28) 100% (120) |
Abbot Vascular (Chicago, IL) | FDA, CE |
| Endeavor® | Co-Cr | Phosphorylcholine polymer | Zotarolimus | 75% (2) 95% (15) 100% (28) |
Metronic (Fridley, MN) | FDA, CE |
| Endeavor® Resolute | Co-Cr | Blend of PVP, poly(hexyl methacrylate)-co-PVP-co-PVAc, and PBMA-co-PVAc (BioLinx) | Zotarolimus | 50% (7) 70% (28) 100% (31) |
Metronic (Fridley, MN) | FDA, CE |
| Firebird 2® | Co-Cr | Poly(styrene-butylene styrene) | Sirolimus | 50% (7) 90% (30) |
Essen Technology (Beijing, China) |
Phase IV NCT01257373 |
Pt-Cr: platinum chromium, SS: stainless steel, Co-Cr: cobalt-chromium, PCh: phosphorylcholine polymer, PEVA: poly(ethylene-co-vinyl acetate), PBMA: poly(n-butyl methacrylate), and CE: Conformité Européenne.